1. Home
  2. BBIO vs PSN Comparison

BBIO vs PSN Comparison

Compare BBIO & PSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BBIO
  • PSN
  • Stock Information
  • Founded
  • BBIO 2015
  • PSN 1944
  • Country
  • BBIO United States
  • PSN United States
  • Employees
  • BBIO N/A
  • PSN N/A
  • Industry
  • BBIO Biotechnology: Pharmaceutical Preparations
  • PSN EDP Services
  • Sector
  • BBIO Health Care
  • PSN Technology
  • Exchange
  • BBIO Nasdaq
  • PSN Nasdaq
  • Market Cap
  • BBIO 8.8B
  • PSN 8.1B
  • IPO Year
  • BBIO 2019
  • PSN 2019
  • Fundamental
  • Price
  • BBIO $49.08
  • PSN $79.84
  • Analyst Decision
  • BBIO Strong Buy
  • PSN Strong Buy
  • Analyst Count
  • BBIO 16
  • PSN 12
  • Target Price
  • BBIO $61.69
  • PSN $88.18
  • AVG Volume (30 Days)
  • BBIO 2.9M
  • PSN 982.1K
  • Earning Date
  • BBIO 08-05-2025
  • PSN 08-06-2025
  • Dividend Yield
  • BBIO N/A
  • PSN N/A
  • EPS Growth
  • BBIO N/A
  • PSN 23.64
  • EPS
  • BBIO N/A
  • PSN 2.23
  • Revenue
  • BBIO $235,812,000.00
  • PSN $6,683,116,000.00
  • Revenue This Year
  • BBIO $106.33
  • PSN N/A
  • Revenue Next Year
  • BBIO $54.30
  • PSN $5.36
  • P/E Ratio
  • BBIO N/A
  • PSN $35.83
  • Revenue Growth
  • BBIO 7.62
  • PSN 9.22
  • 52 Week Low
  • BBIO $21.72
  • PSN $54.56
  • 52 Week High
  • BBIO $51.86
  • PSN $114.68
  • Technical
  • Relative Strength Index (RSI)
  • BBIO 55.76
  • PSN 61.36
  • Support Level
  • BBIO $48.03
  • PSN $77.29
  • Resistance Level
  • BBIO $51.86
  • PSN $80.35
  • Average True Range (ATR)
  • BBIO 1.95
  • PSN 2.15
  • MACD
  • BBIO -0.08
  • PSN -0.08
  • Stochastic Oscillator
  • BBIO 71.55
  • PSN 70.96

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

About PSN Parsons Corporation

Parsons Corp is a provider of technology-driven solutions in the defense, intelligence, and critical infrastructure markets. The business activities of the group are carried out through Federal Solutions and Critical Infrastructure segments. The Federal Solutions segment is a high-end service and technology provider to the U.S. government, delivering timely, cost-effective solutions for mission-critical projects, whereas the Critical Infrastructure segment provides integrated design and engineering services for complex physical and digital infrastructure around the globe.

Share on Social Networks: